UC Davis Comprehensive Cancer Center | Strategic Alliance Partners
UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 100,000 adults and children every year and access to more than 200 active clinical trials at any given time. Its innovative research program engages more than 240 scientists at UC Davis who work collaboratively to advance discovery of new tools to diagnose and treat cancer. Patients have access to leading-edge care, including immunotherapy and other targeted treatments. Its Office of Community Outreach and Engagement addresses disparities in cancer outcomes across diverse populations, and the cancer center provides comprehensive education and workforce development programs for the next generation of clinicians and scientists. For more information, visit cancer.ucdavis.edu.
Latest from UC Davis Comprehensive Cancer Center
Investigating Risk-Based Treatment Strategies for Pediatric Non-Rhabdomyosarcoma Soft-Tissue Sarcoma
July 07, 2024
Article
Robert Lawrence Randall, MD, FACS, discusses the significance of risk-based therapy in patients with non-rhabdomyosarcoma soft tissue sarcoma.
Guideline-Concordant Care Is Associated With Reduced Risk of Death in Metastatic Osteosarcoma
May 14, 2024
Article
R. Lor Randall, MD, FACS, detailed research into the relationship between guideline-concordant care and survival outcomes in patients with osteosarcoma in California.
Examining Potential Markers of Osteosarcoma Stem Cells Is at the Forefront of Research
April 30, 2024
Article
R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with cancer stem cells.
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
April 19, 2024
Article
R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.
Randall Details Inaugural Birmingham Orthopedic Oncology Meeting
March 06, 2024
Article
R. Lor Randall, MD, FACS, discusses the top takeaways from the inaugural 2024 Birmingham Orthopedic Oncology Meeting.
Active Surveillance Is a Safe and Acceptable Treatment Alternative in Select D-TGCT
February 16, 2024
Article
R. Lor Randall, MD, discusses the adequacy of active surveillance for select patients with diffuse-type tenosynovial giant cell tumor.
Chest CT Imaging Patterns Contradict ACR Guidelines for Extremity Sarcoma Staging and Surveillance
February 10, 2024
Article
R. Lor Randall, MD, FACS, explains the next steps in ensuring adherence to clinical care guidelines in extremity sarcoma.
Early-Phase Clinical Research Center Poised to Provide New Benefits in Hawaii and Beyond
February 07, 2024
Article
The University of Hawaii Cancer Center hopes to address treatment needs through its planned Early Phase Clinical Research Center.
Randall Highlights the Evolving Role of Surgery in TGCT Management
January 16, 2024
Article
R. Lor Randall, MD, FACS, discusses the early efficacy seen with vimseltinib monotherapy and pexidartinib plus surgery in tenosynovial giant cell tumors.
Dr Nagasaka on the Efficacy of Repotrectinib in Locally Advanced/Metastatic ROS1+ NSCLC
January 11, 2024
Video
Misako Nagasaka, MD, discusses key data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ non–small cell lung cancer.
Engineered Bone Marrow Shows Preclinical Potential in Osteosarcoma
January 10, 2024
Article
R. Lor Randall, MD, FACS, emphasizes the overall potential for investigating the utility of engineered bone marrow in patients with osteosarcoma.
Cancer Blood Tests Jumpstart Diagnoses and Targeted Therapy
December 21, 2023
Article
New research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.
New California Tobacco Cessation Policy Research Center to be Housed at Cancer Center
October 03, 2023
Article
UC Davis Comprehensive Cancer Center has launched the state’s first-ever Tobacco Cessation Policy Research Center.
Randall Spotlights Surgical and Non-Surgical Advances in Musculoskeletal Oncology
September 12, 2023
Article
R. Lor Randall, MD, FACS, discusses the process of organizing the symposium, key surgical and non-surgical advancements as well as socioeconomic disparities identified in these papers, and the importance of this information for both surgical and medical oncologists.
Gene Therapy Study Identifies Potential New Treatment for Liver Cancer
August 29, 2023
Article
Gene therapy that induces the body to create microRNA-22, a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma, the most common form of liver cancer.
Randall Discusses the Importance of Identifying and Managing Chondroblastoma in Clinical Practice
August 16, 2023
Article
R. Lor Randall, MD, FACS, explains the difference between noncancerous chondroblastoma and other bone neoplasms, details the typical diagnosis and treatment of this rare condition, and emphasizes the importance of pediatric and medical oncologists being able to identify it in clinic.
Global Consensus-Finding Meeting Aims to Improve the Management of Chondrosarcoma Complications
August 04, 2023
Article
R. Lor Randall, MD, FACS, provides details about the 2024 Birmingham Orthopedic Oncology Meeting and its main topic of discussion, explains the rationale for its inception, and emphasizes the importance of this meeting for orthopedic oncologists treating chondrosarcoma.
Pazopanib Associated With Higher Wound Complication Rates in Non-rhabdomyosarcoma Soft Tissue Sarcoma
June 20, 2023
Article
R. Lor Randall, MD, FACS, discusses the use of neoadjuvant pazopanib in patients with non-rhabdomyosarcoma soft tissue sarcoma, expanded on findings from the subgroup analysis of ARST1321, and detailed the implications of these findings.
Dr Randall on One-stage Synovectomy in D-TGCT
June 14, 2023
Video
R. Lor Randall, MD, FACS, discusses findings from a study of one-stage synovectomy in patients with diffuse-type tenosynovial giant cell tumor of the knee.
One-stage Synovectomy Does Not Lead to Worse Outcomes in D-TGCT of the Knee
June 14, 2023
Article
R. Lor Randall, MD, FACS, discusses the standard treatment approach for patients with diffuse-type tenosynovial giant cell tumor, the results of the retrospective cohort study evaluating 1- vs 2-stage synovectomies in these patients, and the importance of having additional treatment options for this patient population.